Abstract: OBJECTIVE To analyze the clinical distribution and drug resistance of Enterococcus spp. , so as to provide guidance for rational use of antibacterial agents. METHODS Enterococcus spp. were clinically isolated and collected from our hospital from Jan. 2010 to Dec. 2014, identified by VITEK-2 Compact automated microbial analysis system, and given GPS-AST67 susceptibility cards to test antibiotics susceptibility. The distribution and antibacterial resistance of Enterococcus spp. were analyzed by WHONET 5.6. RESULTS A total of 482 strains of Enterococcus spp. were isolated from 2010-2014,including 286 strains of Enterococcus faecalis and 153 strains of Enterococcus faecium, and most of these were from urine, drainage liquid and bloodstream. The resistance rates of E. faecalis to ampicillin, penicillin, erythromycin, ciprofloxacin, levofloxacin, moxifloxacin, gentamicin(high concentration), streptomycin(high concentration), nitrofurantoin, vancomycin were 24.1%, 19.2%, 66.4%, 18.5%, 19.2%, 19.2%, 38.1%, 30.4%, 0.3% and 0.3%,which were significantly lower than those of E. faecium (94.1%, 92.2%, 91.5%, 93.5%,88.2%, 89.5%, 70.6%, 49.0%, 40.5% and 2.6%). The resistance rates of E.faecalis to quinupristin/dalfopristin and tetracycline were 100.0% and 76.6%,significantly higher than E.faecium (0.0% and 42.5%).There were no obvious trend changes of drug resistance rate of Enterococcus spp. from 2010 to 2014. CONCLUSION The main distribution of E.faecalis and E.faecium is in urine, drainage liquid and bloodstream, and the resistance rates to a variety of antibacterial agents have large differences, so there should have a rational choice about antibacterial agents based on susceptibility testing in clinic.